^
Association details:
| Biomarker: | PD-L1 underexpression |
|---|---|
| Cancer: | Malignant Pleural Mesothelioma |
| Drug Class: | PD1 inhibitor |
| Direction: | Resistant |
Evidence:
Source:
Title:
Genomic characterization of malignant pleural mesothelioma and associated clinical outcomes
Published date:
11/03/2020
Excerpt:
Median PFS with immunotherapy was poor with at 1.5 months (SD ±0.4). Overall PDL1 expression and TMB is low in patients with MPM resulting in limited benefit from single agent PD-1/PD-L1 agent.
DOI:
10.1016/j.ctarc.2020.100232
